An observational study in Lung Diseases, Lung Neoplasms and Lung Cancer, sponsored by Ambu A/S. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by Ambu A/S · Observational
The primary aim is to develop a software algorithm that has the capacity to detect the normal 18 anatomical structures of the lung by using the position of the scope during the bronchoscopy procedure and using existing bronchoscopy technology.
A data collection of bronchoscopy videos from 100-150 patients are enrolled for getting image material of different lung anatomies, captured with CE-marked and FDA-approved Ambu bronchoscopes (Ambu® aScope™ 5 Broncho HD). No intervention will take place, only standard of care. All types of indications are enrolled. All patients were given oral and written information prior to participating, and signed consent was provided. No patient identifiable information is stored.
3,319 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 115 is below the median of 160 across 939 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →Ambu A/S is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All adults indicated for a bronchoscopy above 18 year is part of the population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention will take place in this study, only image material will be captured from the standard-of-care bronchoscopy
Number of bronchial segments accessed during bronchoscopy
Accurate procedure recordings by the bronchoscope of all 18 anatomical segments +/- abnormalities
Time frame: 1 year
Plan to share: No — The data is collected to develop software, and no intervention will take place. It will therefore not be relevant to share the data with other researchers for further analysis.
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Feb 2024, 3 months.
Of 52 industry-sponsored observational studies under Lung Diseases, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 34. This study's 3 months is below that.
Counting every sponsor, half of 353 studies reached it within 34 months; a quarter within 17 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ambu A/S